Medical Science
| Open Access |
DOI: Laboratory Picture Of The Cardiotoxic Effect Of Immunodepressants Used In The Pathogenetic Therapy Of Patients With Chronic Glomerulonefritis
Muminov Davron Kadirovich , Professor, Department of Internal Medicine, Nephrology and Hemodialysis, Tashkent State Medical University, Uzbekistan. Tashkent State Medical University, Uzbekistan Jalilov Shukhrat Khamidovich , PhD student, Department of Internal Medicine Nephrology and Hemodialysis, Tashkent State Medical University. Nephrologist, Republican Specialized Scientific and Practical Medical Center of Nephrology and Kidney Transplantation, UzbekistanAbstract
The article presents a picture of changes in the side effects of these drugs on the cardiovascular system in 79 patients with glomerulonephritis who were prescribed immunosuppressive therapy of various compositions, using biochemical laboratory analyses as an example of cardiospecific indicators. At the same time, the results of studies on the specifics of the negative effects of immunosuppressive agents on the myocardium in the study groups where hormones and cytostatics were recommended were analyzed. Based on the results of the study, conclusions were drawn and relevant recommendations were formulated.
Keywords
Aspartate aminotransferase, glomerulonephritis, immunosuppressive therapy
References
Vasyuk Yu.A. et al. Consensus statement of Russian experts on the prevention, diagnosis, and treatment of cardiovascular toxicity of anticancer therapy // Russian Journal of Cardiology. – 2021. – Vol. 26, No. 9. – P. 4703. doi:10.15829/1560-4071-2021-4703.
Degtyaryova E.A. et al. Rare immune-mediated adverse events: a literature review // FARMATEKA. – 2020. – No. 7. – P. 8–14. https://dx.doi.org/10.18565/pharmateca.2020.7.8-14
Ivanov D.O. et al. Diseases of the cardiovascular system as a cause of mortality in the Russian Federation: ways to solve the problem // Medicine and Healthcare Organization. – 2019. – Vol. 4, No. 2. – P. 4–12.
Kaprina A.D. et al. The state of oncological care for the population of Russia in 2022. – Moscow: P.A. Herzen Moscow Oncology Research Institute – Branch of the National Medical Research Center of Radiology of the Ministry of Health of Russia. 2022. 239 p.
Kozyavin N.A. et al. Cardiovascular complications of modern anticancer drug therapy: chemotherapy, targeted therapy and immunotherapy (textbook). – St. Petersburg: N.N. Petrov National Medical Research Center of Oncology, 2023. – 82 p. ISBN 978-5-6048250-2-0
Chazova I.E. et al. Eurasian clinical guidelines for the diagnosis, prevention, and treatment of cardiovascular complications in anticancer therapy // Eurasian Journal of Cardiology. – 2022. – Vol. 1, No. 37. – P. 6–79. doi:10.38109/2225-1685-2022-1-6-79.
Sharafeev A.Z. et al. Cardio-oncology – a new direction in cardiology // Practical Medicine. – 2020. – Vol. 18, No. 1. – P. 38–42.
Avila V.S. et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY trial // Journal of the American College of Cardiology. – 2018. – Vol. 71(20). – P. 2281–2290. doi:10.1016/j.jacc.2018.02.049.
Chen D.Y. et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology // Journal of the Formosan Medical Association. – 2020. – Vol. 119(10). – P. 1461–1475. doi:10.1016/j.jfma.2019.07.025.
Ghadri J.R. et al. International expert consensus document on Takotsubo syndrome (Part I): Clinical characteristics, diagnostic criteria, and pathophysiology // European Heart Journal. – 2018. – Vol. 39(22). – P. 2032–2046. doi:10.1093/eurheartj/ehy076.
Lyon A.R. et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO), and the International Cardio-Oncology Society (IC-OS): Developed by the ESC Cardio-Oncology Task Force // European Heart Journal – Cardiovascular Imaging. – 2022. – Vol. 23(41). – P. 4229–4361. doi:10.1093/eurheartj/ehac244.
Lyon A.R. et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools // European Journal of Heart Failure. – 2020. – Vol. 22(11). – P. 1945–1960. doi:10.1002/ejhf.1920.
Mahmood S.S. et al. Myocarditis in patients treated with immune checkpoint inhibitors // Journal of the American College of Cardiology. – 2018. – Vol. 71(16). – P. 1755–1764. doi:10.1016/j.jacc.2018.02.037.
Moslehi J.J. et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis // The Lancet. – 2018. – Vol. 391(10124). – P. 933. doi:10.1016/S0140-6736(18)30533-6.
Patel R.P. et al. Cardiotoxicity of immune checkpoint inhibitors // Current Oncology Reports. – 2021. – Vol. 23(7). – P. 79. doi:10.1007/s11912-021-01070-6.
Zamorano J.L. et al. ESC position paper on cancer treatments and cardiovascular toxicity // Russian Journal of Cardiology. – 2017. – Vol. 3(143). – P. 105–139.
Download and View Statistics
Copyright License
Copyright (c) 2026 Muminov Davron Kadirovich, Jalilov Shukhrat Khamidovich
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.